Clinical Trial Update: SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports results for SL-401 as consolidation therapy in adverse-risk acute myeloid leukemia in first complete remission; the study was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SL-401 (tagraxofusp) (tagraxofusp)

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-21